Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells.

Circulating endothelial cells (CECs) are present in peripheral blood and have been shown to contribute to normal and pathological neovascularization. Antiangiogenic molecules can inhibit neovascularization in tumors and other sites, but their effect on CECs has not yet been determined. We hypothesize that angiogenic factors will increase the number of CECs, and conversely, antiangiogenic treatment will reduce these numbers. Mice treated with high levels of vascular endothelial growth factor (VEGF) showed increased numbers of Flk-1-positive cells in peripheral blood and endothelial cell colonies compared with vehicle-treated controls. These changes were accompanied by increased bone marrow neovascularization. In contrast, mice that received VEGF and endostatin had significantly lower numbers of CECs and reduced bone marrow vascularization. Endostatin-induced apoptosis was probably responsible for the decreased number of CECs. Systemic delivery of a VEGF antagonist, soluble Flt-1, also inhibited the VEGF-induced increase in CECs. These results were further confirmed in a Tie2/LacZ mouse model, in which endostatin reduced the number of beta-galactosidase-expressing peripheral blood mononuclear cells. We propose that endothelial progenitor cells are a novel target for endostatin and suggest that the relative numbers of CECs can serve as a surrogate marker for the biological activity of antiangiogenic treatment.

[1]  S. Soker,et al.  Pancreatic tumor growth is regulated by the balance between positive and negative modulators of angiogenesis , 2004, Angiogenesis.

[2]  Giovanni Martinelli,et al.  Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  S. Soker,et al.  In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. , 2002, Blood.

[4]  Koichi Hattori,et al.  Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.

[5]  Donald W Kufe,et al.  Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Wannemuehler,et al.  Five-color flow cytometric analysis of swine lymphocytes for detection of proliferation, apoptosis, viability, and phenotype. , 2002, Cytometry.

[7]  J. Cherrington,et al.  SU6668 inhibits Flk‐1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  M. Moore.  Putting the neo into neoangiogenesis. , 2002, The Journal of clinical investigation.

[9]  C. Verfaillie,et al.  Origin of endothelial progenitors in human postnatal bone marrow. , 2002, The Journal of clinical investigation.

[10]  J. Folkman,et al.  Angiogenesis-dependent diseases. , 2001, Seminars in oncology.

[11]  J. Enenstein,et al.  Identification and functional assessment of endothelial P1H12. , 2001, The Journal of laboratory and clinical medicine.

[12]  W. Aird,et al.  NHLBI workshop report: endothelial cell phenotypes in heart, lung, and blood diseases. , 2001, American journal of physiology. Cell physiology.

[13]  S. Rafii,et al.  Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.

[14]  G. Wilding,et al.  Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  G. Pruneri,et al.  Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. , 2001, Cancer research.

[16]  S. Rafii,et al.  Vascular Trauma Induces Rapid but Transient Mobilization of VEGFR2+AC133+ Endothelial Precursor Cells , 2001 .

[17]  R. Herbst,et al.  Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin , 2001, Current oncology reports.

[18]  Anthony Atala,et al.  Continuous release of endostatin from microencapsulated engineered cells for tumor therapy , 2001, Nature Biotechnology.

[19]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[20]  S. Rafii,et al.  Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. , 2000, Blood.

[21]  S. Rafii,et al.  Circulating endothelial precursors: mystery, reality, and promise. , 2000, The Journal of clinical investigation.

[22]  W. Gerald,et al.  Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts , 1999, Nature.

[23]  J. Isner,et al.  Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. , 1999, Circulation research.

[24]  J. Isner,et al.  VEGF contributes to postnatal neovascularization by mobilizing bone marrow‐derived endothelial progenitor cells , 1999, The EMBO journal.

[25]  V. Sukhatme,et al.  Endostatin Induces Endothelial Cell Apoptosis* , 1999, The Journal of Biological Chemistry.

[26]  G. Yancopoulos,et al.  Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. , 1998, Immunity.

[27]  Kenneth J. Hillan,et al.  Vascular endothelial growth factor is essential for corpus luteum angiogenesis , 1998, Nature Medicine.

[28]  E. Wayner,et al.  Circulating activated endothelial cells in sickle cell anemia. , 1997, The New England journal of medicine.

[29]  Thomas N. Sato,et al.  Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[31]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[32]  S. Rafii,et al.  Isolation and characterization of human bone marrow microvascular endothelial cells: hematopoietic progenitor cell adhesion , 1994 .

[33]  J. V. van Mourik,et al.  Immunologic detection of endothelial cells in human whole blood. , 1991, Blood.